-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 13, Joincare issued an announcement that the company's salmeterol and ficasone inhalation powder spray, which was declared as a generic drug category 4, was approved for clinical use
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
Salmeterol and ficasone inhalation powder spray is used for the regular treatment of reversible airway obstructive airway diseases , including asthma in adults and children .
The original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
The original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
According to data from Minet.
com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
Sales of salmeterol and ticasone terminals in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, the market for inhalation preparations has attracted much attention
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
Healthyuan inhalation preparation products have entered the harvest period
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
In addition, Joincare's acetylcysteine inhalation solution, tobramycin inhalation solution, formoterol inhalation solution, and terbutaline sulfate inhalation solution have been reported for production and are expected to be approved for marketing in 2022.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Source: Minet database, corporate annual report
Note: The statistics are as of April 13.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 13, Joincare issued an announcement that the company's salmeterol and ficasone inhalation powder spray, which was declared as a generic drug category 4, was approved for clinical use
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
Salmeterol and ficasone inhalation powder spray is used for the regular treatment of reversible airway obstructive airway diseases , including asthma in adults and children .
The original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
The original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
According to data from Minet.
com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
Sales of salmeterol and ticasone terminals in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, the market for inhalation preparations has attracted much attention
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
Healthyuan inhalation preparation products have entered the harvest period
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
In addition, Joincare's acetylcysteine inhalation solution, tobramycin inhalation solution, formoterol inhalation solution, and terbutaline sulfate inhalation solution have been reported for production and are expected to be approved for marketing in 2022.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Source: Minet database, corporate annual report
Note: The statistics are as of April 13.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
On April 13, Joincare issued an announcement that the company's salmeterol and ficasone inhalation powder spray, which was declared as a generic drug category 4, was approved for clinical use
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
.
According to data from Minet.
com, in 2020, the sales of salmeterol and ticasone in public medical institutions in China will exceed 1.
5 billion yuan
.
In 2021, the new sales revenue of Healthyuan Respiratory field will be 577 million yuan.
At present, 3 inhalation preparation products have been selected for the fifth batch of centralized procurement
.
Salmeterol and ficasone inhalation powder spray is used for the regular treatment of reversible airway obstructive airway diseases , including asthma in adults and children .
The original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
Disease Disease Disease Children Children Children Enterprise Enterprise EnterpriseThe original research company is GlaxoSmithKline.
The drug was first approved for import in China in 2001.
It has maintained a dazzling sales situation in the country
.
According to data from Minet.
com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
hospital hospital hospital health health _com, in 2020, the terminal sales of salmeterol and ticasone in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 1.
5 billion yuan.
In the first half of 2021 A year-on-year increase of 5.
75%
.
At present, there are no generic drugs of salmeterol and ficasone in the domestic market, and many domestic companies such as Joincare , Changfeng Pharmaceutical, Primetals, Runsheng Pharmaceutical, Chia Tai Tianqing, and Hengrui are deploying generic drugs
.
Sales of salmeterol and ticasone terminals in public medical institutions in China (unit: ten thousand yuan)
Source: Minet.
com China's public medical institutions terminal competition pattern
com China's public medical institutions terminal competition pattern
In recent years, the market for inhalation preparations has attracted much attention
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
.
According to data from Minet.
com, the sales volume of chemical drug terminal inhalants in China's public medical institutions will be close to 20 billion yuan in 2020, with a year-on-year increase of 37.
61% in the first half of 2021
.
From the perspective of domestic enterprises, the products of Hengrui, Chia Tai Tianqing and other enterprises are relatively mature, and Joincare and Primetals are also making continuous efforts
.
Healthyuan inhalation preparation products have entered the harvest period
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
.
According to the annual report, in 2021, the company's respiratory field will achieve new sales revenue of 577 million yuan, a significant year-on-year increase
.
At present, Joincare has 4 inhalants (7 product specifications) approved for marketing, including ipratropium bromide inhalation solution for inhalation, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation3 This inhalant was selected for the fifth batch of centralized collection
.
In addition, Joincare's acetylcysteine inhalation solution, tobramycin inhalation solution, formoterol inhalation solution, and terbutaline sulfate inhalation solution have been reported for production and are expected to be approved for marketing in 2022.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Among them, tobramycin inhalation solution is expected to become the first antibiotic for inhalation in China; formoterol aerosol and mometasone formoterol aerosol are in clinical stage; Desmonium bromide powder spray, etc.
obtained clinical approval
.
Source: Minet database, corporate annual report
Source: Minet database, corporate annual report Note: The statistics are as of April 13.
If there are any omissions, please correct me!
If there are any omissions, please correct me!
